Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asterand and Allergan in potential $62 million preclinical eye disease deal

This article was originally published in Scrip

Executive Summary

Asterand could receive up to $62.3 million after signing an exclusive licence agreement with Allergan on the development of preclinical compounds for eye diseases. Allergan gains the right to develop and commercialise certain selective, small-molecule prostaglandin receptor agonists from Asterand's R99 development programme to treat conditions such as glaucoma. Allergan will give Asterand an upfront technology access fee of $6.3 million and up to a further $56 million on success-based development and sales milestone payments, plus royalties. Asterand, which provides human tissue and services for drug discovery research, has other drug discovery programmes such as further prostaglandin agonists for immuno-inflammatory diseases and pre-term labour, and compounds for treating bone disease, cancer and irritable bowel syndrome. Martyn Coombs, Asterand CEO, says the company will seek out-licensing opportunities with other pharma companies.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003286

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel